-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 F3MjzJGTzvOGTxeOPzZjuCAnasQ2Wa/fi2he7aE/MHnxMLy/S9CWzXLsykOZyA7p
 mZEFNdTtp8ux02V0cbDAAg==

<SEC-DOCUMENT>0001130319-07-000006.txt : 20070103
<SEC-HEADER>0001130319-07-000006.hdr.sgml : 20070101
<ACCEPTANCE-DATETIME>20070103115024
ACCESSION NUMBER:		0001130319-07-000006
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20070103
FILED AS OF DATE:		20070103
DATE AS OF CHANGE:		20070103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		07502132

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>o34307form6vk.htm
<DESCRIPTION>PRESS RELEASE DATED JANUARY 3, 2007
<TEXT>
<HTML>
<HEAD>
<TITLE>form6vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<HR size="4" noshade color="#000000" style="margin-top: -5px">
<HR size="1" noshade color="#000000" style="margin-top: -10px">

<P align="center" style="font-size: 14pt"><B>SECURITIES AND EXCHANGE COMMISSION<BR>
<DIV align="center" style="font-size: 12pt">Washington, D.C.
20549</DIV></B>


<P align="center" style="font-size: 18pt"><B>Form 6-K</B>

<P align="center" style="font-size: 10pt"><B>Report of Foreign Private Issuer</B>

<P align="center" style="font-size: 10pt"><B>Pursuant to Rule&nbsp;13a-16 or 15d-16<BR>
of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt">For the month of January
2007

<P align="center" style="font-size: 10pt">Commission File Number 000-31062

<CENTER>
<P align="center" style="font-size: 24pt"><B>Oncolytics Biotech Inc.</B>
<HR size="1" width="45%" noshade>
<DIV align="center" style="font-size: 10pt"><I>(Translation of registrant&#146;s name into
English)</I>
</DIV>
</CENTER>

<CENTER>
<P align="center" style="font-size: 10pt"><B>Suite&nbsp;210, 1167 Kensington Crescent NW<BR>
Calgary, Alberta, Canada T2N 1X7</B>
<HR size="1" width="45%" noshade>
<DIV align="center" style="font-size: 10pt"><I>(Address of principal executive offices)</I>
</DIV>
</CENTER>

<P style="font-size: 10pt">Indicate by check mark whether the registrant files or will file annual reports
under cover Form&nbsp;20-F or Form&nbsp;40-F.

<CENTER>
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="70%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD align="center" valign="top">Form&nbsp;20-F&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Form&nbsp;40-F&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#254;</FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</CENTER>

<P style="font-size: 10pt">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as
permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(1):&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT>

<P style="font-size: 10pt"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(1) only permits the submission in paper of a
Form&nbsp;6-K if submitted solely to provide an attached annual report to security
holders.

<P style="font-size: 10pt">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as
permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(7):&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT>

<P style="font-size: 10pt"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(7) only permits the submission in paper of a
Form&nbsp;6-K if submitted to furnish a report or other document that the registrant
foreign private issuer must furnish and make public under the laws of the
jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home
country exchange on which the registrant&#146;s securities are traded, as long as
the report or other document is not a press release, is not required to be and
has not been distributed to the registrant&#146;s security holders, and, if
discussing a material event, has already been the subject of a Form&nbsp;6-K
submission or other Commission filing on EDGAR.

<P style="font-size: 10pt">Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of
1934.

<CENTER>
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="70%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">Yes&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">No&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#254;</FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</CENTER>

<P style="font-size: 10pt">If &#147;Yes&#148; is marked, indicate below the file number assigned to the registrant
in connection with Rule&nbsp;12g3-2(b):&nbsp;&nbsp;&nbsp;82&nbsp;-&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>

<P>
<HR size="1" noshade color="#000000" style="margin-top: -2px">
<HR size="4" noshade color="#000000" style="margin-top: -10px">

<P style="font-size: 10pt">&nbsp;

</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD colspan="9"><A HREF="#000">Signatures</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<!-- link1 "Signatures" -->
<DIV align="left"><A NAME="000"></A></DIV>

<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>

<P style="font-size: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

<P>
<CENTER>
<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD colspan="3" align="left" valign="top"><B>Oncolytics
Biotech Inc.</B><BR>
(Registrant)</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top">Date: January 3, 2007</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Doug Ball
<HR size="1" noshade width="60%">
Doug Ball<BR>
Chief Financial Officer</TD>
</TR>
</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt">&nbsp;

</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="65%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><IMG src="o34307o3430700.gif" alt="(ONCOLYTICS LOGO)">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">210, 1167 Kensington Cr. N.W.<BR>
Calgary, Alberta<BR>
Canada T2N 1X7</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>FOR IMMEDIATE RELEASE</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial<BR>
Investigating
REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> in Combination with Docetaxel</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>CALGARY, AB, &#151; January&nbsp;3, 2007 </B>- Oncolytics Biotech Inc. (&#147;Oncolytics&#148;) (TSX:ONC, NASDAQ:ONCY)
announced today that it has received a letter of approval from the U.K. Medicines and Healthcare
products Regulatory Agency (MHRA)&nbsp;for its Clinical Trial Application (CTA)&nbsp;to begin a clinical
trial using intravenous administration of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> in combination with docetaxel
(Taxotere<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>) in patients with advanced cancers including bladder, prostate, lung and
upper gastro-intestinal. The principal investigator is Professor Hardev Pandha of The Royal Surrey
Hospital, U.K. Docetaxel is used in patients with lung, breast and prostate cancers, and is also
used widely in the treatment of many other types of cancers.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;The trial is expected to yield data that will further characterize responses in these target
patient populations and will help in designing the late-stage development program for
REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>,&#148; said Dr.&nbsp;Brad Thompson, President and CEO of Oncolytics.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In preclinical studies conducted at the U.S. National Cancer Institute (NCI)&nbsp;and Royal Surrey
Hospital in the U.K., the combination of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> </SUP>and various taxanes including
docetaxel has been shown to be synergistic against a variety of cancer cell lines.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The trial (REO 010) has two components. The first is an open-label, dose-escalating,
non-randomized study of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> given intravenously with docetaxel every three weeks.
A standard dosage of docetaxel will be delivered with escalating dosages of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>
intravenously. A maximum of three cohorts will be enrolled in the REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> </SUP>dose
escalation portion. The second component of the trial will immediately follow and will include the
enrolment of a further 12 patients at the maximum dosage of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> in combination
with a standard dosage of docetaxel.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours
such as bladder, lung, prostate or upper gastro-intestinal cancers that are refractory (have not
responded) to standard therapy or for which no curative standard therapy exists. The primary
objective of the trial is to determine the Maximum Tolerated Dose
(MTD), Dose-Limiting Toxicity (DLT), recommended dose and
dosing schedule and safety profile of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> when administered in combination with
docetaxel. Secondary objectives include the evaluation of immune response to the drug combination,
the body&#146;s response to the drug combination compared to chemotherapy alone and any evidence of
anti-tumour activity.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In the U.K. and the U.S., approximately 600,000 people are diagnosed annually with bladder, lung,
prostate and upper gastro-intestinal cancers.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>About Oncolytics Biotech Inc.</B><BR>
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses
as potential cancer therapeutics. Oncolytics&#146; clinical program includes a variety of Phase I and
Phase II human trials using REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>, its proprietary formulation of the human
reovirus, alone and in combination with radiation or chemotherapy. For further information about
Oncolytics, please visit <U>www.oncolyticsbiotech.com</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">For more information about docetaxel (taxotere<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>) please visit <U>www.taxotere.com</U>
</DIV>


<DIV align="left" style="font-size: 8pt; margin-top: 6pt"><I>This press release contains forward-looking statements, within the meaning of Section&nbsp;21E of
the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the
Company&#146;s expectations related to the U.K. combination REOLYSIN</I><SUP style="font-size: 85%; vertical-align: text-top"><I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></I></SUP><I>/docetaxel clinical
trial, and the Company&#146;s belief as to the potential of REOLYSIN</I><SUP style="font-size: 85%; vertical-align: text-top"><I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></I></SUP><I> as a cancer
therapeutic, involve known and unknown risks and uncertainties, which could cause the Company&#146;s
actual results to differ materially from those in the forward-looking statements. Such risks and
uncertainties include, among others, the availability of funds and resources to pursue research and
development projects, the efficacy of REOLYSIN</I><SUP style="font-size: 85%; vertical-align: text-top"><I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></I></SUP><I> as a cancer treatment, the tolerability
of REOLYSIN</I><SUP style="font-size: 85%; vertical-align: text-top"><I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></I></SUP><I> outside a controlled test, the success and timely completion of clinical
studies and trials, the Company&#146;s ability to successfully commercialize REOLYSIN</I><SUP style="font-size: 85%; vertical-align: text-top"><I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></I></SUP><I>,
uncertainties related to the research and development of pharmaceuticals and uncertainties related
to the regulatory process. Investors should consult the Company&#146;s quarterly and annual filings with
the Canadian and U.S. securities commissions for additional information on risks and uncertainties
relating to the forward looking statements. Investors are cautioned against placing undue reliance
on forward-looking statements. The Company does not undertake to update these forward-looking
statements.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>FOR FURTHER INFORMATION PLEASE CONTACT:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Oncolytics Biotech Inc.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The Equicom Group
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The Investor Relations Group</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Cathy Ward
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Nick Hurst
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Damian McIntosh</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">210, 1167 Kensington Cr NW
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">600, 205 5<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Ave. SW
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">11 Stone St, 3rd Floor</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Calgary, Alberta T2N 1X7
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Calgary, Alberta T2P 2V7
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">New York, NY 10004</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Tel: 403.670.7377
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: 403.538.4845
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: 212.825.3210</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Fax: 403.283.0858
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 403.266.2453
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 212.825.3229</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><U>cathy.ward@oncolytics.ca</U>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><U>nhurst@equicomgroup.com</U>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><U>dmcintosh@investorrelationsgroup.com</U></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">-30-
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>o34307o3430700.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o34307o3430700.gif
M1TE&.#EA\@`W`/<``/______S/__F?__9O__,___`/_,___,S/_,F?_,9O_,
M,__,`/^9__^9S/^9F?^99O^9,_^9`/]F__]FS/]FF?]F9O]F,_]F`/\S__\S
MS/\SF?\S9O\S,_\S`/\`__\`S/\`F?\`9O\`,_\``,S__\S_S,S_F<S_9LS_
M,\S_`,S,_\S,S,S,F<S,9LS,,\S,`,R9_\R9S,R9F<R99LR9,\R9`,QF_\QF
MS,QFF<QF9LQF,\QF`,PS_\PSS,PSF<PS9LPS,\PS`,P`_\P`S,P`F<P`9LP`
M,\P``)G__YG_S)G_F9G_9IG_,YG_`)G,_YG,S)G,F9G,9IG,,YG,`)F9_YF9
MS)F9F9F99IF9,YF9`)EF_YEFS)EFF9EF9IEF,YEF`)DS_YDSS)DSF9DS9IDS
M,YDS`)D`_YD`S)D`F9D`9ID`,YD``&;__V;_S&;_F6;_9F;_,V;_`&;,_V;,
MS&;,F6;,9F;,,V;,`&:9_V:9S&:9F6:99F:9,V:9`&9F_V9FS&9FF69F9F9F
M,V9F`&8S_V8SS&8SF68S9F8S,V8S`&8`_V8`S&8`F68`9F8`,V8``#/__S/_
MS#/_F3/_9C/_,S/_`#/,_S/,S#/,F3/,9C/,,S/,`#.9_S.9S#.9F3.99C.9
M,S.9`#-F_S-FS#-FF3-F9C-F,S-F`#,S_S,SS#,SF3,S9C,S,S,S`#,`_S,`
MS#,`F3,`9C,`,S,```#__P#_S`#_F0#_9@#_,P#_``#,_P#,S`#,F0#,9@#,
M,P#,``"9_P"9S`"9F0"99@"9,P"9``!F_P!FS`!FF0!F9@!F,P!F```S_P`S
MS``SF0`S9@`S,P`S````_P``S```F0``9@``,P``````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````"'Y!```````+`````#R`#<```C_``$('$BPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6&*S)FO,BQH\>/($.*I&B%2R!6UZ#-NG8-):M`
M5E:,G$FSILV;%U><O!:-):M9UEK):GEM:,N8.),J7<J4XXJ?UJX)5<FJ5*"K
MK++V1#DTD,RF8,.*9>I2ZDLK"E=88=6*Z,NQ<./*O;C6+5*':HG.8O5UKM^_
M@`4&*AJ-%=J).EE!.QJXL>.F.HEZS8D(Y;7#CS-K%CDX*^:+)#I?WDRZ=$71
MGSNB-LVZM4(K1:_U!0E;5K39KG.;7A'-=FJ0@7JSTDW<-"O;@6RBC,:EN//'
M=5D9L!F#55#<S[/#13D+^\A`0)-K_Q\_%C:TX3A70&M+OCW8K+-^T^PLWKU]
MFT];+ETQ%/W]_R/5M@=9O0%H8$@[R5=3(+X=Z"!'+GE7DX`(77450E5<)6%!
M5IR4U5D;"J26AUG!%"(`.L'$4(<:)L3B9RQ:*..,V*6H($$C?HB(B@DE]F&)
M=QWD$F2S1',(0L<)=U`7*-V(HF4E[E24@FNY]%(@B*C$&$)UU:=09WP=-)@L
M_@F4E5MHEO5;EU]"N6,I9X;)(906PJ>2EP.MT%*92J7$YT"L]+:507IL*29+
MDQ6TD9@1&O145][!EI5#@^V%6V>F,-3H0I+^*:)+7>"V*(<^U:@60OQ=@V=2
M/WD*P'&7;?\JD!4K*>C2JISVIU`I;>%J15</!;*8G*^R=*2F0YT(P*^J'O24
M2D]`Q."D$?$F"ZXW68:D5``P6%A?YG5QT%I[2812*T[6=IM!5O26:;"V\179
M6PT%VMV*[AXZBQ[56AF3LB(6B:U-K5CCJF+7"&:-I;,V>>AYU<ZR6(C\];:F
M;<?"N^=*`QL$E;*_&GD040`;Y.$U*[%RR+\]+EP*6&8A"50`@D5CL$RUR3=F
MQ\ZB;`T+"I5`V)KY1K23=3P7I-B]G!:-8ZD5=7AF3RT=(N&03/%G,)(J]<5%
M6WQ5T9;.\59[WF@]VA8?NQA/M),@$?TDVXIM>XQ2#!ZIM5S"0K;_5/)'[<XR
M8-_0S%8;*RQ8$XU\UA)+Z9ZO]0;-`>P6]:[1+:T2-S2R@&RYOI=W]&@KWNWT
MMT>!%&SK+$P/U&Y+M7*YE9-]H^WHN8",&VC&$.TQ%-P0R0WR[@>5<,AB5N<=
MJ#61HLSO4M:U,AWAV-7%^8WDGF=%3-N79`KC.\'T;XZ&DDIF]^@'>1`7O;T<
M?-<K?EYAH-=NK];V+1+D4O=JC=B?@GJB5E)4@#)H).1,D9(;[:2V$K>88F4N
M.HG$)N@N+FRH+E1CB0;GEA`]%(EW]9+8\)K5HT"8HBPN.42B1(25#4+)%"OL
M6^MN<@7D*$0%"R%!M4;E$!)H9`4X?!"._S2"EXRPK"&_@AA.`J"XS@GQB161
M"O-P4IND0?&*)@N*JT#R%)2<#HM8W)]R$`7&,CJD+AP<"2"$LL4\H4@D/.S1
M&P$FDY+%T5D$T:'H&/)%$?7Q4"B9B14*MCA-&>8D/`L$"&\G/L.DI4/7XM'\
MKK*]A5"R0R%*XPPI\I00P48\:UF(C3K4$5@YKB.#7)@5S\*BA7`A=(Y*(P!L
MEQ!9SJ]["Z%7O<1G!6C0#B-\<Y%A^!+*A!B`EJ)CB]\`=XV@6/%57M%;B/:P
M2!PY4D2R@`)#2,<0#=VQ(!=RR&4TLDG$G))#LE@6*P#1QA)<DXMG0B9B1/-,
M:'8OANSBF4ZZMY*'7[X*9+QTT@JN`(CN!1%)?3FG1)["*?2L0!#Z#.AK%+HM
ME.`3(FM16SW-R%&3$4557^RB%/W9T9(Z2F*R*-@[2\B=/?W1I"8USUY\PLKM
MF80M05G8>5X*TYY&IX!`*5A;;";%5I0";SU-:D5&I)*<`J4W>S&14J?JE!]J
8I`14S:I6M\K5KGKUJV`-JUC'NM6````[
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
